Entest BioMedical

Entest BioMedical develops immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine.

Entest BioMedical, Inc. engages in the development and commercialization of immunotherapeutic therapies for the veterinary market. The company is developing ImenVax family of canine cancer vaccines, which include ImenVax I, a therapeutic for canine cancer, which is involved in isolating tumor cells from the patient and placing the cells into a cell implant device that is inserted subcutaneously into the patient; ImenVax II that utilizes cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat existing tumors through stimulation of immune responses. It is also developing ENT-576 therapy for the treatment of chronic obstructive pulmonary disease. In addition, the company operates veterinary hospitals. Entest BioMedical, Inc. was founded in 2008 and is based in La Mesa, California.